A novel near-infrared (NIR) diffuse correlation spectroscopy (DCS) for tumor blood flow measurement is introduced in this review paper. DCS measures speckle fluctuations of NIR diffuse light in tissue, which are sensitive to the motions of red blood cells. DCS offers several attractive new features for tumor blood flow measurement such as noninvasiveness, portability, high temporal resolution, and relatively large penetration depth. DCS technology has been utilized for continuous measurement of tumor blood flow before, during, and after cancer therapies. In those pilot investigations, DCS hemodynamic measurements add important new variables into the mix for differentiation of benign from malignant tumors and for prediction of treatment outcomes. It is envisaged that with more clinical applications in large patient populations, DCS might emerge as an important method of choice for bedside management of cancer therapy, and it will certainly provide important new information about cancer physiology that may be of use in diagnosis.
|Journal||Journal of Biomedical Optics|
|State||Published - Jan 2012|
Bibliographical noteFunding Information:
The author thanks the National Institutes of Health (NIH) R01 CA149274 and National Center for Research Resources (NCRR) UL1RR033173. Most of data presented in this paper were collected from Dr. Arjun G. Yodh’s laboratory and the hospital at the University of Pennsylvania. The author also gratefully acknowledges discussions and interactions with numerous scientists in the biomedical optics community, including Arjun G. Yodh, Turgut Durduran, Chao Zhou, Ulas Sunar, Hsing-wen Wang, Xiaoman Xing, Regine Choe, Theresa M. Busch, Steven M. Hahn, Timothy C. Zhu, Jarod C. Finlay, Harry Quon, and Mahesh Kudrimoti.
- Blood flow
ASJC Scopus subject areas
- Electronic, Optical and Magnetic Materials
- Atomic and Molecular Physics, and Optics
- Biomedical Engineering